<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375217</url>
  </required_header>
  <id_info>
    <org_study_id>ANES.MA.14</org_study_id>
    <nct_id>NCT02375217</nct_id>
  </id_info>
  <brief_title>&quot;Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy&quot;</brief_title>
  <official_title>&quot;Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Randomized non inferiority Trial involving adult patients undergoing elective
      surgery under general anesthesia.56 Patients will be enrolled in 2 groups : full dose
      sugammadex vs half dose sugammadex for reversal of NMB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' aim is to prove that half dose sugammadex in combination with neostigmine
      0.05 mg/kg is non-inferior to the recommended dose of sugammadex for the reversal of deep (
      absence of Trian of Four response :TOF) or moderate ( TOF 1 or 2 twiches) muscle paralysis in
      patients undergoing surgery under general anesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TOF ratio of 0.9</measure>
    <time_frame>within 5 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the time to return of TOF ratio to 0.9 and the time till extubation</measure>
    <time_frame>within 10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual neuro-muscular blockade</measure>
    <time_frame>within 10 to 180 mins</time_frame>
    <description>Post Anesthesia recovery unit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Anesthesia Recovery</condition>
  <arm_group>
    <arm_group_label>Group 1 : (NS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 Drug combination:
patients receive half of the recommended dose of sugammadex plus dose of neostigmine&quot;
Sugammadex IV= -1 mg/kg( moderate NMB) or
2 mg/kg (deep NMB)
neostigmine IV = 50mcg/kg
glycopyrrolate 10 mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : (S)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receive Full recommended dose of sugammadex
Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>half dose</description>
    <arm_group_label>Group 1 : (NS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>full dose</description>
    <arm_group_label>Group 2 : (S)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>IV = 50mcg/kg</description>
    <arm_group_label>Group 1 : (NS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycopyrrolate</intervention_name>
    <arm_group_label>Group 1 : (NS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-70

          -  ASA class I, II, and III

          -  undergoing surgery under balanced general anesthesia requiring the use of muscle
             relaxants throughout the surgery

        Exclusion Criteria:

          -  patients undergoing emergency surgeries

          -  pregnant patients

          -  patients with end stage renal disease or chronic kidney disease(GFR less than 60)

          -  patients with allergy to sugammadex or who had previous complications or side effects
             from previous sugammadex administration

          -  patients' refusal

          -  patients with allergy to recuronium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Mn Aouad,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Mn Aouad,, MD</last_name>
    <phone>961 1350000</phone>
    <phone_ext>6380/1</phone_ext>
    <email>mm01@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>AUBMC</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Aouad, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Marie Awad</investigator_full_name>
    <investigator_title>Professor of clinical Specialty</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

